Shenzhen YHLO Biotech Co Ltd
SSE:688575

Watchlist Manager
Shenzhen YHLO Biotech Co Ltd Logo
Shenzhen YHLO Biotech Co Ltd
SSE:688575
Watchlist
Price: 15.53 CNY Market Closed
Market Cap: 8.9B CNY

Net Margin
Shenzhen YHLO Biotech Co Ltd

8.3%
Current
18%
Average
1.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
8.3%
=
Net Income
154.8m
/
Revenue
1.9B

Net Margin Across Competitors

No Stocks Found

Shenzhen YHLO Biotech Co Ltd
Glance View

Market Cap
8.9B CNY
Industry
Health Care

In the bustling city of Shenzhen, a beacon of China's rapid technological advancement, YHLO Biotech Co Ltd has emerged as a dynamic player in the healthcare diagnostics industry. Founded in 2008, YHLO Biotech focuses on the development, manufacturing, and distribution of in-vitro diagnostic products. By leveraging cutting-edge immunodiagnostic technologies, the company spearheads innovations in autoimmune disease diagnostics, infectious disease testing, and respiratory pathogen detection. Driven by a commitment to precision and reliability, YHLO Biotech integrates advanced automation solutions and robust biological research to produce diagnostic kits that serve hospitals, laboratories, and research institutions across the globe. YHLO Biotech's business model revolves around an intricate blend of product sales and strategic partnerships. By establishing a diverse portfolio of diagnostic instruments and reagent kits, they cater to both public and private healthcare sectors. The company also engages in collaborations with international diagnostic companies, enhancing its global footprint and broadening market access. Revenue generation at YHLO Biotech is primarily rooted in the sale of these diagnostic solutions, which are consistently updated to meet evolving medical standards and demands. Coupled with their investment in R&D and a rigorous quality control process, YHLO Biotech not only maintains a competitive edge but also fortifies its position as a trusted entity within the medical diagnostics landscape.

Intrinsic Value
22.82 CNY
Undervaluation 32%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
8.3%
=
Net Income
154.8m
/
Revenue
1.9B
What is the Net Margin of Shenzhen YHLO Biotech Co Ltd?

Based on Shenzhen YHLO Biotech Co Ltd's most recent financial statements, the company has Net Margin of 8.3%.

Back to Top